The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanomaKesang Li, Jinyan Wang, Yingyi Ye et al.|Biomaterials Science|2020Cited by 47
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trialYan Zhao, Jianzhong Zhang, Hong Ren et al.|Allergy|2024Cited by 30
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Jianzhong Zhang, Congjun Jiang et al.|British Journal of Dermatology|2024Cited by 21
Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trialLunfei Liu, Min Zheng, Chunlei Zhang et al.|European Journal of Dermatology|2020Cited by 5
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Jianzhong Zhang, Litao Zhang et al.|Advances in Therapy|2025Cited by 3